Table 1. Characteristics of patients.
| Characteristic | TT/TC (n=120) | CC (n=60) | P value |
|---|---|---|---|
| Lipid lowering medications | |||
| Without medications | 62 (51.7) | 22 (36.7) | |
| Atorvastatin | 49 (40.8) | 32 (53.3) | 0.17a |
| Simvastatin | 4 (3.3) | 1 (1.7) | |
| Gemfibrozil | 5 (4.2) | 5 (8.3) | |
| Antidiabetic agents | |||
| Without medications | 8 (6.7) | 5 (8.3) | |
| Metformin | 42 (35.0) | 21 (35.0) | 0.98a |
| Glibenclamide | 6 (5.0) | 3 (5.0) | |
| Metformin+Glibenclamide | 64 (53.3) | 31 (51.7) | |
| Age, yr | 52.98±6.80 | 56.00±5.89 | 0.004b |
| BMI, kg/m2 | 29.59±4.63 | 29.35±4.24 | 0.74b |
| WC, cm | 92.57±10.96 | 91.73±10.39 | 0.62b |
| Physical activity, MET, time/day | 38.91±5.92 | 37.44±4.39 | 0.08b |
| Food intake | |||
| Energy, kcal/day | 2,524.80±815.66 | 2,646.87±1,056.31 | 0.43b |
| Carbohydrate, g/day | 334.87±115.35 | 358.42±174.42 | 0.48c |
| Protein, g/day | 88.10±27.28 | 90.77±38.24 | 0.74c |
| Fat, g/day | 100.75±44.23 | 104.16±51.20 | 0.70c |
| Polyunsaturated fatty acid, g/day | 23.95±12.86 | 26.15±16.50 | 0.60c |
| Monounsaturated fatty acid, g/day | 34.56±17.12 | 35.04±18.35 | 0.49c |
| Saturated fatty acid, g/day | 26.98±10.71 | 25.86±9.67 | 0.06c |
| Lipid profile | |||
| Triglycerides, mmol/L | 2.12±1.36 | 1.88±1.24 | 0.25b |
| Total cholesterol, mmol/L | 5.17±1.90 | 4.99±2.57 | 0.59b |
| HDL-C, mmol/L | 1.36±0.29 | 1.41±0.36 | 0.45b |
| LDL-C, mmol/L | 2.86±1.00 | 2.81±0.95 | 0.73b |
Values are presented as number (%) or mean±standard deviation.
BMI, body mass index; WC, waist circumference; MET, metabolic equivalent of task; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
aUsing the chi-square test, bUsing the independent t-test, cUsing the analysis of covariance (adjusted for energy).